1.Jacopo Fanizza 1, Ferdinando D'Amico 1 2, Gaetano Lauri 1, Samuel J Martinez-Dominguez 3, Mariangela Allocca 1, Federica Furfaro 1, Alessandra Zilli 1, Gionata Fiorino 1, Tommaso Lorenzo Parigi 1, Simona Radice 1, Laurent Peyrin-Biroulet 4 5, Silvio Danese 1. The role of filgotinib in ulcerative colitis and Crohn's disease. https://pubmed.ncbi.nlm.nih.gov/38009327/. 2023
2.Davide Giuseppe Ribaldone 1, Laura Parisio 2, Angela Variola 3, Fabrizio Bossa 4, Fabiana Castiglione 5, Manuela Marzo 6, Nicole Piazza 7, Annalisa Aratari 8, Edoardo Vincenzo Savarino 9, Giorgia Bodini 10, Mauro Mastronardi 11, Federica Micheli 12, Silvia Mazzuoli 13, Marta Ascolani 14, Chiara Viganò 15, Maria Cappello 16, Cristina Bezzio 17, Rachele Ciccocioppo 18, Giulia Scardino 19, Ennio Sarli 20, Daniela Pugliese 2, Franco Scaldaferri 2, Daniele Napolitano 2, Alessia Todeschini 3, Andrea Geccherle 3, Nicoletta Colaci 21, Maria Guerra 4, Monica Annese 4, Anna Testa 5, Anna Caiazzo 5, Francesco Simone Conforti 7, Stefano Festa 8, Greta Lorenzon 9, Antonella Marra 11, Ambra Magiotta 12, Flavia Baccini 12, Arnaldo Amato 22, Anxhela Poshnjari 23, Marta Vernero 23, Flavio Caprioli 24, Gian Paolo Caviglia 23; Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study. https://pubmed.ncbi.nlm.nih.gov/37474412/. 2023